Preclinical studies with toremifene as an antitumor agent

[1]  S. Robinson,et al.  Inhibition of hormone-dependent and independent breast cancer cell growthin vivo andin vitro with the antiestrogen toremifene and recombinant human interferon-α2 , 1990, Breast Cancer Research and Treatment.

[2]  O. Dahl,et al.  Aminoglutethimide treatment in advanced breast cancer: An efficient therapy as a late endocrine alternative in a sequential therapeutic approach , 2005, Breast Cancer Research and Treatment.

[3]  M. Perilä,et al.  A new triphenylethylene compound, Fc-1157a , 1986, Cancer Chemotherapy and Pharmacology.

[4]  M. Perilä,et al.  A new triphenylethylene compound, Fc-1157a , 1986, Cancer Chemotherapy and Pharmacology.

[5]  E. Borden,et al.  Differential ability of antiestrogens to stimulate breast cancer cell (MCF-7) growth in vivo and in vitro. , 1989, Cancer research.

[6]  S. Robinson,et al.  Antiestrogenic action of toremifene on hormone-dependent, -independent, and heterogeneous breast tumor growth in the athymic mouse. , 1989, Cancer research.

[7]  S. Robinson,et al.  Antitumor actions of toremifene in the 7,12-dimethylbenzanthracene (DMBA)-induced rat mammary tumor model. , 1988, European journal of cancer & clinical oncology.

[8]  S. Legha,et al.  Tamoxifen in the treatment of breast cancer. , 1988, Annals of internal medicine.

[9]  P. Rissanen,et al.  Toremifene, a new antiestrogenic compound, for treatment of advanced breast cancer. Phase II study. , 1988, European journal of cancer & clinical oncology.

[10]  Jack Cuzick,et al.  Effects of adjuvant tamoxifen and of cytotoxic therapy on mortality in early breast cancer. An overview of 61 randomized trials among 28,896 women , 1988 .

[11]  S. Robinson,et al.  Metabolism of steroid-modifying anticancer agents. , 1988, Pharmacology & therapeutics.

[12]  W. Holleran,et al.  Quantitation of Toremifene and its Major Metabolites in Human Plasma by High-Performance Liquid Chromatography Following Fluorescent Activation , 1987 .

[13]  I. Screpanti,et al.  Estrogen and antiestrogen modulation of the levels of mouse natural killer activity and large granular lymphocytes. , 1987, Cellular immunology.

[14]  S. Robinson,et al.  Species-specific pharmacology of antiestrogens: role of metabolism. , 1987, Federation proceedings.

[15]  V. Jordan.  Estrogen/Antiestrogen Action and Breast Cancer Therapy , 1986 .

[16]  L. Andersson,et al.  The oestrogen antagonists, tamoxifen and FC-1157a, display oestrogen like effects on human lymphocyte functions in vitro. , 1985, Clinical and experimental immunology.

[17]  V. Jordan.  Biochemical pharmacology of antiestrogen action. , 1984, Pharmacological reviews.

[18]  B. Furr,et al.  The pharmacology and clinical uses of tamoxifen. , 1984, Pharmacology & therapeutics.

[19]  J. Revillard,et al.  Sex steroid receptors in peripheral T cells: absence of androgen receptors and restriction of estrogen receptors to OKT8-positive cells. , 1983, Journal of immunology.

[20]  V. Jordan,et al.  Laboratory studies to develop general principles for the adjuvant treatment of breast cancer with antiestrogens: Problems and potential for future clinical applications , 1983, Breast cancer research and treatment.

[21]  V. Jordan,et al.  Pharmacology of tamoxifen in laboratory animals. , 1980, Cancer treatment reports.

[22]  C. Riccardi,et al.  Natural Killer Cells: Characteristics and Regulation of Activity , 1979, Immunological reviews.

[23]  I. Todd,et al.  A New Anti-oestrogenic Agent in Late Breast Cancer: An Early Clinical Appraisal of ICI46474 , 1971, British Journal of Cancer.